TScan Therapeutics (NASDAQ:TCRX) Downgraded to Sell Rating by Wall Street Zen

TScan Therapeutics (NASDAQ:TCRX) was downgraded by Wall Street Zen from a “hold” rating to a “sell” rating in a report released on Saturday.

A number of other research analysts have also recently commented on TCRX. HC Wainwright reduced their target price on shares of TScan Therapeutics from $15.00 to $10.00 and set a “buy” rating on the stock in a research report on Wednesday, May 7th. Barclays reduced their target price on shares of TScan Therapeutics from $14.00 to $3.00 and set an “overweight” rating on the stock in a research report on Friday, March 7th. Needham & Company LLC reissued a “buy” rating and set a $9.00 target price on shares of TScan Therapeutics in a research report on Tuesday, April 8th. Wedbush reissued an “outperform” rating and set a $7.00 target price on shares of TScan Therapeutics in a research report on Tuesday, May 6th. Finally, Morgan Stanley reissued an “overweight” rating and set a $10.00 target price on shares of TScan Therapeutics in a research report on Friday, March 14th. One equities research analyst has rated the stock with a sell rating and five have given a buy rating to the stock. Based on data from MarketBeat.com, TScan Therapeutics currently has an average rating of “Moderate Buy” and a consensus target price of $7.80.

TScan Therapeutics Trading Down 3.7%

Shares of TCRX stock opened at $1.55 on Friday. The stock has a market cap of $87.72 million, a price-to-earnings ratio of -1.46 and a beta of 0.98. The company has a quick ratio of 9.56, a current ratio of 9.56 and a debt-to-equity ratio of 0.13. TScan Therapeutics has a fifty-two week low of $1.02 and a fifty-two week high of $9.08. The firm’s 50 day moving average price is $1.45 and its two-hundred day moving average price is $2.13.

TScan Therapeutics (NASDAQ:TCRX) last posted its earnings results on Monday, May 12th. The company reported ($0.26) EPS for the quarter, topping analysts’ consensus estimates of ($0.28) by $0.02. TScan Therapeutics had a negative net margin of 1,188.88% and a negative return on equity of 58.72%. The business had revenue of $2.17 million for the quarter, compared to analysts’ expectations of $1.62 million. On average, analysts anticipate that TScan Therapeutics will post -1.12 EPS for the current year.

Insider Activity at TScan Therapeutics

In other TScan Therapeutics news, major shareholder Lynx1 Capital Management Lp bought 1,200,000 shares of the stock in a transaction on Tuesday, May 20th. The stock was purchased at an average price of $1.20 per share, for a total transaction of $1,440,000.00. Following the completion of the purchase, the insider now directly owns 7,946,141 shares in the company, valued at approximately $9,535,369.20. This trade represents a 17.79% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 4.35% of the stock is currently owned by corporate insiders.

Institutional Trading of TScan Therapeutics

Institutional investors have recently added to or reduced their stakes in the business. BNP Paribas Financial Markets bought a new stake in TScan Therapeutics during the fourth quarter valued at $198,000. ProShare Advisors LLC bought a new stake in TScan Therapeutics during the fourth quarter valued at $40,000. Prudential Financial Inc. bought a new stake in TScan Therapeutics during the fourth quarter valued at $32,000. Barclays PLC increased its stake in TScan Therapeutics by 16.3% during the fourth quarter. Barclays PLC now owns 67,508 shares of the company’s stock valued at $206,000 after purchasing an additional 9,441 shares during the last quarter. Finally, Wellington Management Group LLP increased its stake in TScan Therapeutics by 5.2% during the fourth quarter. Wellington Management Group LLP now owns 132,895 shares of the company’s stock valued at $404,000 after purchasing an additional 6,550 shares during the last quarter. Institutional investors own 82.83% of the company’s stock.

About TScan Therapeutics

TScan Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation.